Our top pick for
aTyr Pharma, Inc is a biotechnology business based in the US. aTyr Pharma shares (LIFE) are listed on the NASDAQ and all prices are listed in US Dollars. aTyr Pharma employs 40 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$2.93 - $7.93|
|50-day moving average||$4.47|
|200-day moving average||$4.20|
|Wall St. target price||$15.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-10.21|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$10.5 million|
|Gross profit TTM||$-6,836,000|
|Return on assets TTM||-26.55%|
|Return on equity TTM||-61.82%|
|Market capitalisation||$66 million|
TTM: trailing 12 months
There are currently 884,479 aTyr Pharma shares held short by investors – that's known as aTyr Pharma's "short interest". This figure is 30.6% up from 677,271 last month.
There are a few different ways that this level of interest in shorting aTyr Pharma shares can be evaluated.
aTyr Pharma's "short interest ratio" (SIR) is the quantity of aTyr Pharma shares currently shorted divided by the average quantity of aTyr Pharma shares traded daily (recently around 2.0 million). aTyr Pharma's SIR currently stands at 0.44. In other words for every 100,000 aTyr Pharma shares traded daily on the market, roughly 440 shares are currently held short.
However aTyr Pharma's short interest can also be evaluated against the total number of aTyr Pharma shares, or, against the total number of tradable aTyr Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case aTyr Pharma's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 aTyr Pharma shares in existence, roughly 60 shares are currently held short) or 0.0643% of the tradable shares (for every 100,000 tradable aTyr Pharma shares, roughly 64 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against aTyr Pharma.
Find out more about how you can short aTyr Pharma stock.
We're not expecting aTyr Pharma to pay a dividend over the next 12 months.
aTyr Pharma's shares were split on a 1:14 basis on 30 June 2019. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your aTyr Pharma shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for aTyr Pharma shares which in turn could have impacted aTyr Pharma's share price.
Over the last 12 months, aTyr Pharma's shares have ranged in value from as little as $2.93 up to $7.929. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while aTyr Pharma's is 2.1164. This would suggest that aTyr Pharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.
aTyr Pharma, Inc. , a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product ATYR1923 is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co. , Ltd.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.